MT Newswires After-Hours News Movers
5:53PM ET 1/27/2020 MT NewswiresSome of the stocks moving on news-driven events in Monday's after-hours include: XLRN, +68.34% SURF, +13.79% DESP, +8.76% GGG, +4.57% CNCE, +2.22% BRO,...
Quotes Snapshot > ALEC
Alector Inc ALEC:NASDAQ
Last Price$25.73NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/27/20
Today's Change+1.18(4.81%)
Bid (Size)$24.80 (3)
Ask (Size)$25.00 (4)
Day Low / High$24.40 - 26.07
Volume914.8 K
Read more news Recent News
Alector Plans to Sell About 5.1 Million Shares - Stock Down Almost 5% After-Hours
5:18PM ET 1/27/2020 MT NewswiresAlector (ALEC), a clinical-stage biotechnology company, said on Monday it plans to sell about 5.1 million shares in an underwritten public offering through...
Alector Starts Dosing in Trial of Treatment for Alzheimer's, Parkinson's
12:00PM ET 1/06/2020 MT NewswiresBiotechnology company Alector Inc. (ALEC) said Monday that it has initiated the dosing of patients in its Phase 1 study of AL101 last month. The trial is...
Alector Hires Former Theravance Senior Vice President as Chief Operating Officer
5:21PM ET 12/11/2019 MT NewswiresAlector (ALEC) late Wednesday said it has named Dr. Shehnaaz Suliman to be its new chief operating officer, with the former Theravance Biopharma (TBPH)...
View all Commentary and Analysis
Alector: A Promising Neuro-Immunology Pick For 2020
8:00PM ET 1/27/2020 Seeking AlphaNetflix, Cisco And Chewy On The Marquee (Stocks To Watch Podcast)
7:30AM ET 12/08/2019 Seeking AlphaStocks To Watch: Netflix, Cisco And Chewy On The Marquee
9:03AM ET 12/07/2019 Seeking AlphaBuy Bellus Health Before It Hits The Nasdaq
5:06PM ET 9/15/2019 Seeking AlphaCompany Profile
Business DescriptionAlector, Inc. operates as a clinical-stage biopharmaceutical company. It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA. View company web site for more details
| Address | 151 Oyster Point Boulevard South San Francisco, California 94080 |
| Phone | +1.415.231.5660 |
| Number of Employees | N/A |
| Recent SEC Filing | 01/27/2020 4 |
| Chief Executive Officer & Director | Arnon Rosenthal |
| President & Chief Operating Officer | Shehnaaz Suliman |
| Chief Financial & Accounting Officer | Calvin Yu |
| Chief Medical Officer | Robert Paul |
Company Highlights
| Price Open | $24.77 |
| Previous Close | $24.55 |
| 52 Week Range | $13.64 - 27.00 |
| Market Capitalization | $1.8 B |
| Shares Outstanding | 68.9 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/24/2020 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.51 |
| Beta vs. S&P 500 | N/A |
| Revenue | $27.7 M |
| Net Profit Margin | -378.57% |
| Return on Equity | -43.73% |
Analyst Ratings as of 01/27/2020
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |